An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.
This study is an extension of a previous trial, looking further into the long-term safety and how well a drug called mexiletine works for individuals with Myotonic Dystrophy Type 1 or Type 2. If you've already finished the initial MEX-DM-302 study and meet certain health requirements, you might be invited to join this extension. All participants in this part of the study will receive the active medication, not a dummy pill, for an additional 18 months. Doctors will carefully monitor your health and how the treatment affects your symptoms over time.
A colpo d'occhio
Di cosa tratta questo studio?
This study is about a medication called mexiletine, which is being tested for people living with Myotonic Dystrophy, specifically types 1 and 2. Myotonic Dystrophy is a condition that causes muscles to weaken and stop working properly over time.
This particular study is an 'extension' of a previous trial. This means that if you've already taken part in the earlier study (called MEX-DM-302) and found the treatment helpful, your doctors might invite you to continue receiving mexiletine for another 18 months. The main goal is to see if the medication continues to be safe and how well it works over a longer period.
It's important to understand that in this extension study, everyone will receive the active drug. There won't be a placebo (dummy pill) group. This allows researchers to gather more information about mexiletine's long-term effects, helping them understand if it can be a helpful treatment option for people with Myotonic Dystrophy.
Punti chiave
- This study is for people with Myotonic Dystrophy Type 1 or 2 who completed a previous trial.
- It aims to understand the long-term safety and effectiveness of mexiletine.
- All participants will receive the active drug for 18 months, not a placebo.
- The dose will be adjusted to suit you, taken once daily.
- Regular health checks, including heart monitoring, are a key part of participating.
- Puoi smettere di partecipare in qualsiasi momento.
Chi può essere idoneo?
You might be able to join this study if you have Myotonic Dystrophy Type 1 or Type 2, and your diagnosis has been confirmed by genetic tests. A key requirement is that you must have already completed the previous MEX-DM-302 study.
To be considered, you'll need to be at least 16 years old. Your general health will be assessed, and doctors will check for any heart problems or other serious medical conditions that might make taking part unsafe. For example, if you have severe kidney problems or uncontrolled diabetes, you likely wouldn't be able to join.
There are also some requirements related to your physical abilities, such as having enough strength in your fingers to perform certain tests and not experiencing a lot of falls. If you are a woman who could become pregnant, you would need to use effective birth control throughout the study.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- Do you have Myotonic Dystrophy Type 1 or Type 2, confirmed by genetic tests?
- Have you already completed the MEX-DM-302 study?
- Hai 16 anni o più?
- Do you have good general health, especially no serious heart problems?
- Are you able to follow study instructions and attend all appointments?
- If female, are you able to use effective birth control during the study?
Cosa comporta la partecipazione?
If you join this study, you'll continue to take the mexiletine medication once a day, usually in the morning with food. The dose will start lower and gradually increase over the first couple of weeks to find the best amount for you, which could be up to a maximum of 500mg. Your doctors will adjust the dose if you have any side effects.
Throughout the study, which will last for an additional 18 months, you'll have regular check-ups. These will involve talking to your doctors about any side effects you might be experiencing. They will also do various tests to check your overall health, including blood tests, physical examinations, and checking your blood pressure and pulse. To specifically monitor your heart health, you'll have ECGs (heart rhythm tests), Holter monitors (small devices that record your heart rhythm over a day or two), and echocardiograms (ultrasound scans of your heart).
The study involves regular visits to the clinic for these assessments and to collect more medication. You'll need to be committed to attending all scheduled appointments until the study ends.
Rischi e benefici potenziali
Luoghi (6)
- Laboratory for Muscle Diseases and NeuropathiesCodice postale verificatoLovanio, Belgio
- Aarhus University HospitalCodice postale verificatoAarhus, Danimarca
- Ludug-Maximilians UniversityCodice postale verificatoMonaco di Baviera, Germania
- Azienda Ospedaliera Universitaria Policlinico Tor VergataCodice postale verificatoRome, Italy
- University Hospital of MadridCodice postale verificatoMadrid, Spagna
- University College HospitalCodice postale verificatoLondra, Regno Unito
Domande comuni
What is Myotonic Dystrophy?
Myotonic Dystrophy is a condition that causes muscles to become weak and unable to relax properly. It's a type of muscular dystrophy that can affect many parts of the body.
What is mexiletine and how does it work?
Mexiletine is a medication that helps with certain electrical signals in the body. In Myotonic Dystrophy, it's being studied to see if it can help with muscle stiffness and weakness.
Will I get a dummy pill in this study?
No, in this particular extension study, all participants will receive the active mexiletine medication, not a dummy pill (placebo).
How long will I take the medication?
If you join this extension study, you will take the medication for an additional 18 months after completing the previous study.
What health checks will be done?
You'll have regular checks including blood tests, physical exams, and tests to monitor your heart, such as ECGs and echocardiograms.
Come saperne di più
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Interessato a partecipare?
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.